Toxoplasma gondii has immunostimulant properties. In fact, a chronic infection by a parasite, or even by parasitic extracts, would be capable of inducing resistance to various types of infectious organisms including parasites and yeasts. The induction of resistance to certain types of tumours is also the subject of discussion.
When inducing the activation of adaptive immunity and cytokine production within an infected organism, the T. gondii strains induce cross-protection in relation to a wide range of infectious agents.
This explains VitamFero decision to exploit these properties by using T. gondii for the preparation of live attenuated vaccines.
As a result of its collaboration with the François Rabelais University in Tours, the patented technology (Toxo Mic1-3KO) of VitamFero consists of the selective, total and irreversible removal of certain virulent genes thanks to a sophisticated genetic engineering technique.
These strains can then be used as vectors of simultaneous expression of heterologous antigens. Used in this manner, they are able to induce a strong immune response and can be used to prevent many parasitic infections.
This technology also aims to produce vaccine strains whose effectiveness and safety remain stable over time. In fact, the elimination of virulent genes - as opposed to their inactivation - helps prevent the risk of their reactivation and thereby maintains effectiveness over the long term.
- Aenean eget mi eget
- Sed arcu eros lacinia
- Duis dictum purus
- Integer sodales justo
- Etiam in sem et lectus